tirzepatide heart failure Effects of on the Clinical Trajectory of Patients With Failure, Preserved Ejection Fraction, and Obesity Lilly's Tirzepatide Reduced Heart Failure

(World Health Organization, Geneva, 1992)

The evidence indicates that liraglutide remains effective in pediatric obesity, including adolescents and younger children, and that orforglipron produces clinically meaningful weight or HbA1c reductions in adults with obesity or early type 2 diabetes (Kelly et al., 2020), (Fox et al., 2025), (Wharton et al., 2023), (Rosenstock et al., 2025)

North America has dominated the market for semaglutide biosimilars and generics due to a high number of cases of Type 2 Diabetes and Obesity coupled with higher levels of awareness and adoption of new treatments

Regulatory bodies (MHRA, EMA) do not list immune suppression as a recognised adverse effect in product information

The glucagon receptor component is what truly sets retatrutide apart

Sep 30 2021;18(19)doi:10.3390/ijerph181910309